Ashwagandha For Sleep Quality Research

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

RD

By Gabriela Mitchell, Registered Dietitian (Linkedin)

Last Updated July 2026  ·  28 min read

10% off · weekly tips

Real science on cortisol, stress, and sleep.

Send it →

---

Table of Contents

• What Is Ashwagandha and Why Are Researchers Studying It for Sleep?
• The Clinical Trial Landscape: Key Studies Explained
• KSM-66 and Sleep Quality: The Standardized Extract Evidence
• Breaking Down the Bioactive Compounds: Withanolides and Triethylene Glycol
• Sleep Metrics Researchers Actually Measure
• What the 2021 Meta-Analysis Really Tells Us
• Who Benefits Most? Subgroup Analysis
• Dosage, Timing, and Duration: What the Data Shows
• Safety Profile and Known Limitations
• Frequently Asked Questions
• The Bottom Line: Translating Research Into Practice

---

Introduction

Every year, tens of millions of people lie awake staring at the ceiling, cycling through the same exhausting loop of wakefulness, frustration, and dread. The market for sleep solutions — from prescription sedatives to weighted blankets — generates billions of dollars annually, yet dissatisfaction with available options remains stubbornly high. Into this landscape steps an ancient adaptogenic herb that has suddenly become the subject of rigorous scientific scrutiny.

Ashwagandha for sleep quality research has accelerated dramatically over the past decade, shifting from anecdotal Ayurvedic tradition into peer-reviewed clinical investigation. The question is no longer simply whether ashwagandha helps people sleep — early evidence suggests it does — but rather how it works, for whom it works best, and what dose is necessary to produce clinically meaningful improvements.

This article is written for the scientifically curious reader who wants to understand the actual research, not just the headlines. We will dissect specific clinical trials, explain the sleep metrics researchers use to measure outcomes, examine the pharmacology of the herb's active compounds, and give you an honest assessment of where the evidence is strong, where it is preliminary, and where significant gaps remain.

---

What Is Ashwagandha and Why Are Researchers Studying It for Sleep?

Withania somnifera — commonly known as ashwagandha, Indian ginseng, or winter cherry — is a small shrub native to India, the Middle East, and parts of Africa. Its root extract has been used in Ayurvedic medicine for over 3,000 years primarily as a rasayana, a class of preparations believed to promote longevity, vitality, and resilience to stress.

The modern scientific interest in ashwagandha for sleep is rooted in several converging observations:

1. Its Latin species name literally means "sleep-inducing." The species descriptor somnifera derives from the Latin somnus (sleep) and ferre (to bring). Ancient practitioners clearly recognized its sedative-adjacent properties, and contemporary researchers have taken that observation seriously enough to design controlled trials around it.

2. Its adaptogenic mechanism intersects directly with the neurochemistry of sleep. Chronic psychological stress is one of the most reliable predictors of poor sleep. Elevated cortisol — the primary stress hormone — suppresses the natural cortisol decline that is supposed to occur in the evening, disrupting the hypothalamic-pituitary-adrenal (HPA) axis rhythm that governs sleep architecture. Ashwagandha has demonstrated cortisol-lowering effects in multiple trials, creating a plausible biological bridge between stress reduction and sleep improvement.

3. Specific bioactive compounds appear to interact with sleep-regulating neural pathways. Unlike many botanicals where the active constituents remain poorly characterized, researchers have identified specific molecules in ashwagandha — particularly withanolides and triethylene glycol — that appear to act on GABA receptors and other sleep-relevant neurological targets. This mechanistic specificity has made it a more tractable subject for pharmacological research.

4. The global sleep crisis has created research funding and public interest. With the World Health Organization declaring inadequate sleep a global epidemic, funding bodies and commercial interests have increased investment in sleep interventions that might offer alternatives or complements to pharmaceuticals. Ashwagandha, with its established safety profile in short-term use and growing consumer adoption, became a natural candidate for formal study.

The convergence of traditional use, plausible mechanism, safety data, and substantial market interest has produced a body of ashwagandha sleep research that, while still relatively young, is now substantive enough to analyze with some confidence.

---

★★★★★ 4.8 · 1,247 reviews

Feel Calm By Bedtime. Focused By Morning.

Adaptogen-based formula. Third-party tested. Made in an FDA-registered facility. Backed by a 60-day money-back guarantee.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

The Clinical Trial Landscape: Key Studies Explained

The Randhawa et al. (2020) Randomized Controlled Trial

Perhaps the most frequently cited primary study in the ashwagandha sleep clinical literature is the Randhawa et al. (2020) double-blind, randomized, placebo-controlled trial. This study enrolled adults with self-reported insomnia and randomized them to receive either ashwagandha root extract or matching placebo over a defined treatment period.

The results were striking by the standards of botanical supplement research:

• 72% of participants in the treatment group reported improvement in overall sleep quality
• 29% of participants in the placebo group reported the same improvement
• This difference reached high statistical significance at p < 0.001, meaning there is less than a 1 in 1,000 probability that the difference occurred by chance

The study also documented significant improvements in sleep efficiency, total sleep time, and sleep latency after just 6 weeks of supplementation. These are not soft, subjective measures. Sleep efficiency — the ratio of time spent asleep to time spent in bed — is considered one of the most clinically meaningful sleep metrics because it captures the quality of the sleep period rather than simply its duration.

The magnitude of the placebo group's response (29%) is worth pausing on. A response rate nearly one-third of participants in the control arm is actually quite typical for sleep studies and reflects the enormous impact of expectation, ritual, and attention on perceived sleep quality. The fact that the ashwagandha group showed effects more than twice the size of the placebo effect, with statistical significance, is therefore meaningful.

Badhiwala et al. (2019): Establishing the Effective Dose

The Badhiwala et al. (2019) trial made an important specific contribution to ashwagandha insomnia study literature by testing a precise dosing protocol: 300 mg of root extract taken twice daily, totaling 600 mg per day. This study found significant improvements in both sleep quality and sleep onset latency in participants diagnosed with insomnia.

The 300 mg twice-daily protocol has since become something of a benchmark in the field, informing dosage recommendations in subsequent research and contributing to the emerging consensus that 600 mg/day represents a clinically relevant threshold.

The Animal Research: Mechanistic Insights

A 2022 hydroalcoholic extract study using mouse models reported findings that, while not directly translatable to humans, provide useful mechanistic context:

• A dosage equivalent to 50 mg/kg body weight produced a 34% decrease in sleep onset time
• The same dosage produced a 47% increase in total sleep duration

These animal findings are significant not because they establish human dosing — they cannot — but because they demonstrate that the sleep-promoting effects of ashwagandha extract are robust enough to be detected under controlled laboratory conditions, supporting the plausibility of the human trial results.

KSM-66 and Sleep Quality: The Standardized Extract Evidence

When researchers discuss KSM-66 sleep outcomes in the clinical literature, they are referring to a specific, proprietary full-spectrum root extract that has undergone more formal clinical testing than perhaps any other commercially available ashwagandha preparation. Understanding why KSM-66 occupies a distinct position in the research requires a brief detour into extract standardization.

Why Extract Standardization Matters for Research

Raw ashwagandha root varies substantially in its concentration of active compounds depending on growing conditions, harvest timing, soil composition, and post-harvest processing. This variability creates a fundamental problem for clinical research: if two trials use different preparations, any differences in outcomes might reflect differences in the extract rather than differences in participants, doses, or protocols.

Standardized extracts like KSM-66 solve this problem by guaranteeing minimum concentrations of specific marker compounds — in this case, withanolides — through a validated extraction process. When a trial specifies KSM-66 sleep outcomes, readers can be confident that the dosage reported in the study corresponds to a reproducible, characterized preparation.

KSM-66 Sleep Quality: What the Trials Show

Studies specifically using KSM-66 have consistently demonstrated:

• Statistically significant improvements in Pittsburgh Sleep Quality Index (PSQI) scores — a widely validated self-report measure used in both clinical practice and research
• Reductions in sleep onset latency (the time to fall asleep)
• Improvements in morning alertness and next-day cognitive function, suggesting that the sleep achieved is of sufficient quality to support restorative processes
• A generally favorable side effect profile consistent with the broader ashwagandha safety literature

The KSM-66 preparation has been specifically used in trials examining both clinical insomnia populations and healthy adults experiencing general sleep dissatisfaction, allowing researchers to begin mapping out for whom the intervention is most effective.

KSM-66 and the Stress-Sleep Axis

One of the most methodologically rigorous contributions of KSM-66 sleep quality research has been documenting the parallel reduction in cortisol and improvement in sleep metrics. Several trials measuring both outcomes simultaneously have found that improvements in sleep quality are temporally correlated with measurable reductions in morning serum cortisol, adding mechanistic credibility to the hypothesis that ashwagandha's sleep benefits are mediated at least partly through HPA axis modulation.

This stress-sleep mechanistic pathway is particularly relevant for a large subgroup of poor sleepers: those whose insomnia is driven primarily by hyperarousal, anxiety, and inability to disengage from rumination. For this group, interventions that directly target cortisol dysregulation may be more effective than interventions targeting the sleep system more directly.

★★★★★ 4.8 · 1,247 reviews

The Adaptogens Your Nervous System Has Been Missing.

Ashwagandha, rhodiola, and phosphatidylserine — clinically-studied ingredients that support healthy cortisol rhythms.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Breaking Down the Bioactive Compounds: Withanolides and Triethylene Glycol

Withanolides: The Primary Marker Compounds

Withanolide sleep research has focused primarily on these steroidal lactones as the principal bioactive constituents of ashwagandha. Withanolides are a structurally diverse family of compounds — over 300 have been identified in various Withania species — but research has concentrated on a smaller subset present in the root in pharmacologically significant concentrations.

The mechanisms through which withanolides may influence sleep include:

GABA-A Receptor Modulation: Several withanolides have demonstrated GABA-A receptor binding activity in in vitro and animal studies. GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter, and the GABA-A receptor is the target of benzodiazepines and related sedative drugs. A natural compound capable of positive allosteric modulation of this receptor — enhancing GABA's inhibitory effect without fully mimicking a pharmaceutical agonist — would be expected to produce mild anxiolytic and sleep-facilitating effects at appropriate concentrations.

Hypothalamic-Pituitary-Adrenal Axis Regulation: Withanolides appear to influence HPA axis activity through multiple mechanisms, including modulation of stress-response gene expression and cortisol synthesis. The downstream effects on sleep architecture are significant because dysregulated cortisol is a primary driver of sleep fragmentation and early morning awakening.

Anti-inflammatory Activity: Emerging research has identified neuroinflammation as a contributor to sleep disruption, particularly in aging populations. Withanolides' well-documented anti-inflammatory properties — primarily through NF-κB pathway inhibition — represent a third plausible sleep-relevant mechanism, though this pathway is less well-characterized in the sleep context than the previous two.

The clinical implication of withanolide pharmacology for consumers is that standardized extracts — those guaranteeing minimum withanolide concentrations — are more likely to produce consistent, replicable sleep effects than non-standardized preparations. This is why the withanolide sleep research literature has increasingly converged on standardized extracts as the preferred intervention.

Ashwagandha Triethylene Glycol Sleep: A Distinct Mechanism

Perhaps the most intriguing recent development in ashwagandha sleep pharmacology has been the identification of ashwagandha triethylene glycol sleep effects as a distinct and potentially primary mechanism.

Triethylene glycol (TEG) is a small polyol molecule found in ashwagandha leaf and root extracts. A landmark series of studies, notably from Japanese research groups, used fractionation techniques to isolate individual ashwagandha constituents and test each fraction's sleep-inducing properties independently. The finding was unexpected: while withanolides showed stress-reducing and anxiolytic effects, it was the triethylene glycol fraction that produced the most potent and direct sleep-inducing effects in animal models.

Specifically, ashwagandha triethylene glycol sleep research demonstrated:

• TEG-enriched fractions significantly increased non-rapid eye movement (NREM) sleep duration
• Effects appeared to involve adenosine pathway modulation — the same basic mechanism underlying caffeine's wakefulness-promoting effects, but in the opposite direction
• The sleep induction effects of TEG were observable even in subjects without elevated stress or anxiety, suggesting this mechanism operates independently of the cortisol/stress pathway

This distinction matters clinically. If triethylene glycol is responsible for a significant portion of ashwagandha's sleep-inducing effects through an adenosine-mediated mechanism, then different types of poor sleepers may be responding to different aspects of the same plant extract. Those with stress-driven insomnia may benefit primarily from withanolide-mediated cortisol reduction, while those with primary sleep initiation difficulty may benefit more from triethylene glycol's direct sleep-promoting activity.

This mechanistic heterogeneity may explain why ashwagandha shows benefits across such diverse populations and why the effect sizes, while meaningful, are more modest than single-mechanism pharmaceutical interventions — the extract is doing multiple different things simultaneously.

Sleep Metrics Researchers Actually Measure

To evaluate ashwagandha sleep research intelligently, it helps to understand the specific outcome measures researchers use. Many readers encounter terms like "sleep latency" and "WASO" without a clear understanding of what they mean or why they matter clinically.

Sleep Latency: The Falling Asleep Problem

Ashwagandha sleep latency refers to the time elapsed between lying down with the intention to sleep and the onset of the first sleep stage. In clinical practice, sleep onset latency of more than 20–30 minutes on a regular basis is considered abnormal and is one of the diagnostic criteria for insomnia disorder.

In clinical trials, sleep latency can be measured in two ways:

• Subjectively via sleep diary, where participants record their estimated time to fall asleep
• Objectively via polysomnography (PSG) or actigraphy, which provide physiological measurements

Most ashwagandha trials have used subjective diary measures, which are adequate for capturing the patient experience but may not perfectly correspond to physiological sleep onset. The Randhawa (2020) and Badhiwala (2019) trials both reported significant reductions in sleep latency, suggesting that participants subjectively experienced falling asleep more easily and quickly.

WASO: The Staying Asleep Problem

Ashwagandha WASO — where WASO stands for Wake After Sleep Onset — measures the total time a person spends awake after initially falling asleep and before the final morning awakening. WASO is distinguished from sleep latency because it captures a different clinical problem: not difficulty initiating sleep, but difficulty maintaining it.

High WASO is particularly prevalent in older adults and in individuals with anxiety disorders, where the arousal system remains too active throughout the night, producing frequent brief awakenings that fragment sleep architecture. Each awakening typically suppresses slow-wave sleep and REM sleep, producing the characteristic symptom of unrefreshing sleep — waking exhausted despite spending adequate time in bed.

Ashwagandha WASO reductions have been observed in several trials, though this outcome has received somewhat less attention in the published literature than sleep latency improvements. The mechanistic story for WASO improvement is somewhat different from the latency story: reducing WASO likely requires sustained overnight neurochemical effects rather than the acute sleep-initiation effects associated with TEG.

Sleep Efficiency

Sleep efficiency = (Total Sleep Time ÷ Total Time in Bed) × 100

A sleep efficiency of 85% or above is generally considered normal. Values below 85% indicate that a disproportionate amount of time in bed is being spent awake. Sleep efficiency is a particularly useful clinical measure because it accounts for both sleep latency (time awake before sleep onset) and WASO (time awake during the night) simultaneously, providing an integrated assessment of sleep continuity.

The Randhawa (2020) trial reported significant improvements in sleep efficiency, which — given its mathematical composition — implies improvements in both the latency and WASO dimensions simultaneously.

Pittsburgh Sleep Quality Index (PSQI)

The PSQI is a validated 19-item self-report questionnaire that generates a global score from 0 to 21, with higher scores indicating worse sleep quality. A global score above 5 is the standard threshold for clinically significant sleep impairment. The PSQI captures multiple dimensions including sleep duration, sleep disturbance, sleep latency, daytime dysfunction, and subjective sleep quality, making it the most comprehensive single-instrument sleep assessment used in supplementation trials.

Multiple ashwagandha trials have used PSQI as a primary outcome, and the convergence of significant improvements across multiple independent research groups using the same validated instrument strengthens confidence in the overall finding.

What the 2021 Meta-Analysis Really Tells Us

Meta-Analytic Methodology: Why This Matters

A meta-analysis pools the results of multiple individual studies using statistical techniques that account for differences in sample size, study quality, and measurement approaches. The resulting effect size estimate is more reliable than any individual study because it is based on more total data and is less likely to be driven by the idiosyncratic characteristics of any single trial.

The 2021 Lopresti et al. meta-analysis published in PLoS ONE represents the most rigorous quantitative synthesis of the ashwagandha sleep clinical evidence base available as of this writing.

The SMD of -0.59: What It Actually Means

The headline finding of the Lopresti meta-analysis was a Standardized Mean Difference (SMD) of -0.59 for overall sleep outcomes, with a 95% confidence interval of -0.75 to -0.42.

For readers unfamiliar with SMD as a statistical measure:

• An SMD of 0.2 is conventionally considered a small effect
• An SMD of 0.5 is conventionally considered a medium effect
• An SMD of 0.8 is conventionally considered a large effect

An SMD of -0.59 therefore represents an effect size approaching medium — meaningful from a clinical perspective, particularly for a botanical intervention. The negative sign simply indicates that the ashwagandha groups scored better (lower on impairment scales, or higher on quality scales) than the control groups.

The 95% confidence interval (-0.75 to -0.42) being entirely on one side of zero (not crossing zero) indicates that the positive effect was statistically robust — the result is unlikely to represent random variation. This is a more conservative and reliable indicator of real effect than the p-value from any single trial.

What the Meta-Analysis Identified as Moderators of Effect

Critically, the Lopresti meta-analysis did not simply confirm that ashwagandha improves sleep — it went further to identify the conditions under which effects are largest:

1. Clinical insomnia status matters: Effects were more prominent in adults with diagnosed insomnia than in healthy adults with subclinical sleep complaints. This does not mean ashwagandha is ineffective in non-insomnia populations — studies in healthy adults do show benefits — but the effect size is larger in those with more significant baseline impairment.

2. Dosage threshold: Effects were strongest at 600 mg/day or higher. This finding, consistent with the Badhiwala (2019) dose-ranging trial, suggests a minimum effective dose threshold and argues against the very low doses sometimes found in multi-ingredient supplement blends.

3. Duration dependency: A minimum of 8 weeks of supplementation was associated with the most pronounced effects. This is important information for realistic expectation-setting: consumers who try ashwagandha for two or three weeks and report minimal benefit may simply not have reached the treatment duration at which clinical trials consistently show significant results.

Who Benefits Most? Subgroup Analysis

Adults with Clinical Insomnia

The research most consistently supports ashwagandha's efficacy in adults meeting criteria for insomnia disorder — defined as difficulty initiating or maintaining sleep on at least three nights per week for at least three months, causing significant distress or functional impairment. For this population, the combination of stress-reducing, cortisol-lowering, and direct sleep-promoting mechanisms creates a particularly favorable set of biological targets.

The magnitude of benefit (72% improvement in self-reported sleep quality vs. 29% placebo) in the Randhawa insomnia trial is among the stronger effect sizes reported for any botanical supplement in this indication.

Healthy Adults Under Chronic Stress

A secondary group showing consistent benefit in ashwagandha sleep clinical trials is healthy adults who report chronic psychological stress as a primary contributor to their sleep difficulties. For this population, the cortisol-lowering and HPA axis-normalizing effects of ashwagandha appear to translate into improved sleep quality even in the absence of frank insomnia disorder.

Several trials specifically recruiting "stressed but otherwise healthy" adults have reported significant PSQI improvements, reductions in sleep onset latency, and improvements in morning alertness. The effect sizes in these trials are generally somewhat smaller than in insomnia populations but are still clinically meaningful.

Older Adults

Aging is associated with predictable changes in sleep architecture: reduced slow-wave sleep, earlier circadian timing, more fragmented sleep with higher WASO, and reduced sleep efficiency. Some evidence suggests ashwagandha may be particularly beneficial in this population because the age-related sleep changes overlap with the specific metrics most responsive to ashwagandha supplementation (efficiency, WASO, sleep onset latency).

Additionally, older adults may be more likely to benefit from ashwagandha's anti-inflammatory effects given the well-documented relationship between elevated neuroinflammation markers and sleep disruption in aging populations.

Where Evidence Is Weaker

The current evidence base is less robust for:

• Children and adolescents (essentially no clinical trial data)
• Shift workers with circadian rhythm-based sleep disruption (the mechanisms involved differ substantially from the primarily stress/anxiety-driven insomnia most studied)
• Athletes with exercise-induced sleep disruption (though some evidence suggests ashwagandha's cortisol-reducing effects may be relevant here)

★★★★★ 4.8 · 1,247 reviews

See Why Athletes And Executives Take It Daily.

Adaptogen-based formula, third-party tested, made in the USA. Cancel subscription anytime.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Dosage, Timing, and Duration: What the Data Shows

Effective Dose Range

The clinical trial literature most consistently demonstrates efficacy at 500–600 mg/day of a standardized root extract. This can be achieved as:

• A single 600 mg dose once daily
• 300 mg twice daily (the Badhiwala protocol)

Lower doses (150–300 mg/day total) have shown less consistent results in the ashwagandha sleep clinical literature, while doses above 600 mg have not been extensively studied and are not clearly associated with additional benefit.

The meta-analysis finding that ≥600 mg/day is associated with larger effects has important practical implications. Many commercially available products contain ashwagandha at doses below this threshold, either as a single ingredient at insufficient dosing or as part of a multi-ingredient formula where each ingredient is present at subclinical levels. Readers evaluating products should examine the total ashwagandha dose specifically.

When to Take It: Timing Considerations

The research literature provides less definitive guidance on timing than on dose. Logical arguments exist for both morning and evening administration:

Evening/Bedtime Rationale: Direct sleep-promoting effects, particularly those mediated through triethylene glycol's adenosine pathway activity, might be most relevant when taken 30–60 minutes before the intended sleep time.

Morning Rationale: Cortisol-lowering effects may be most beneficial when timed to blunt the morning cortisol awakening response (CAR), the natural spike in cortisol that occurs 20–45 minutes after waking, which in chronically stressed individuals can remain elevated throughout the day and into the evening.

Twice-Daily Protocol Rationale: The Badhiwala (2019) protocol of 300 mg twice daily (morning and evening) arguably captures both mechanisms — morning dosing addresses HPA axis dysregulation throughout the day, while evening dosing supports direct sleep onset. This protocol's clinical performance supports it as a reasonable default recommendation pending more specific timing studies.

Duration Required for Effect

This is perhaps the most practically important finding for consumer expectation management: meaningful sleep benefits in clinical trials emerge most consistently after 6–8 weeks of consistent supplementation, with the meta-analysis identifying ≥8 weeks as the duration associated with most prominent effects.

This timeline is substantially longer than consumers typically expect from supplements and is important context for product marketing claims that imply rapid effects. The mechanistic basis for this gradual timeline is plausible — HPA axis normalization and changes in cortisol regulation pattern are processes that occur over weeks rather than days.

The clinical implication is that ashwagandha should be evaluated as a medium-to-long-term sleep support strategy rather than an acute sleep aid analogous to melatonin or a pharmaceutical sedative.

Safety Profile and Known Limitations

Established Safety Data

The safety profile of ashwagandha in clinical trials is generally favorable, particularly for short to medium-term use:

• Well tolerated for up to 3 months in the majority of clinical trials
• Most common adverse events are mild gastrointestinal complaints (nausea, loose stools), typically resolving with dose reduction or taking the supplement with food
• No clinically significant interactions with common medications have been established in controlled trial conditions, though the mechanism-based potential for interactions with sedatives and thyroid medications warrants caution

Known Limitations and Uncertainties

Long-term safety is not established. The "well tolerated up to 3 months" finding is reassuring for short-term use but does not speak to safety over years of continuous supplementation. This is a genuine evidence gap that consumers and clinicians should acknowledge.

Rare case reports of liver injury exist. Several case reports in the medical literature have described hepatotoxic reactions potentially associated with ashwagandha supplementation. The causality in most cases is uncertain — patients were often taking multiple supplements — but the signal is sufficient to warrant attention, particularly in individuals with pre-existing liver conditions.

Thyroid hormone interactions. Ashwagandha may increase thyroid hormone levels, which is relevant for individuals with hyperthyroidism or those taking thyroid medications. Clinical monitoring is advisable in this population.

Contraindicated in pregnancy. Traditional use and limited pharmacological data suggest uterine stimulant activity; ashwagandha should not be used during pregnancy.

Research Limitations in the Current Evidence Base

The clinical evidence base, while more substantial than for many botanical supplements, has meaningful methodological limitations:

• Most trials are short-duration (6–12 weeks), limiting conclusions about long-term efficacy
• Polysomnography (objective physiological sleep measurement) has been used in fewer trials than subjective measures; most conclusions rest on self-report data
• Sample sizes in individual trials are generally small, increasing uncertainty around effect size estimates
• Publication bias — the tendency for positive trials to be published while negative trials remain unpublished — cannot be fully excluded

Frequently Asked Questions

How much ashwagandha should I take for sleep?

The clinical trial evidence most consistently supports 500–600 mg per day of a standardized root extract. This dose can be taken as a single daily dose or divided into two doses of 250–300 mg each. Preparations standardized to minimum withanolide content (typically 5% or higher) are recommended based on the pharmacological importance of these compounds. Doses below 300 mg/day have less consistent evidence behind them for sleep outcomes specifically.

How long does it take to work?

This is one of the most important questions for setting realistic expectations. While some individuals report subjective improvements within the first few weeks, the clinical trial data most consistently demonstrates significant, measurable sleep improvements after 6 to 8 weeks of consistent daily use. The meta-analysis specifically identified ≥8 weeks as the duration associated with the largest effect sizes. Consider a minimum trial period of 8 weeks before evaluating efficacy.

Does ashwagandha help people without insomnia?

Yes, multiple trials have shown sleep quality improvements in healthy adults without diagnosed insomnia. However, as the meta-analysis confirmed, effects are more pronounced in those with clinical insomnia than in those with subclinical sleep complaints. If your sleep problems are mild, you may experience more modest benefits, though improvements in subjective sleep quality, morning alertness, and next-day function have been reported even in healthy populations.

Is ashwagandha safe to take long-term?

Clinical trials have established a good safety profile for up to approximately 3 months of continuous use. Long-term safety data beyond this window is limited. For practical purposes, many practitioners suggest a periodic break (e.g., a 2–4 week pause every 3 months) in the absence of long-term safety data, though this is a precautionary recommendation rather than an evidence-based guideline. Individuals with liver conditions, thyroid disorders, or autoimmune conditions should consult a healthcare provider before use.

How does ashwagandha help with sleep?

The current mechanistic evidence points to at least three distinct pathways:

1. Cortisol reduction and HPA axis normalization — reducing chronic stress-hormone elevation that disrupts sleep architecture
2. GABA-A receptor modulation via withanolides — enhancing inhibitory neurotransmission to reduce neurological arousal
3. Adenosine pathway modulation via triethylene glycol — directly promoting sleep induction through a mechanism analogous to (but opposite in direction from) caffeine

The multiplicity of mechanisms may explain both ashwagandha's broad clinical benefits and its more modest effect sizes compared to single-mechanism pharmaceuticals — the herb is doing several things simultaneously at levels that are individually modest but collectively meaningful.

What is the difference between KSM-66 and other ashwagandha extracts?

KSM-66 is a proprietary full-spectrum root extract standardized to minimum withanolide concentrations through a validated cold-water extraction process. It is the most extensively clinically studied specific ashwagandha preparation and has the most robust evidence base for sleep outcomes specifically. Other standardized extracts (such as Sensoril, which uses both root and leaf) also have clinical evidence behind them, but for sleep outcomes specifically, KSM-66 has a particularly well-documented clinical record. Non-standardized ashwagandha powders and extracts of unclear potency are less likely to deliver consistent clinical effects.

★★★★★ 4.8 · 1,247 reviews

Ready To Try Adaptogen-Based Cortisol Support?

Third-party tested. 60-day guarantee. Free shipping over $40. Ships in 24 hours.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

The Bottom Line: Translating Research Into Practice

After reviewing the available clinical evidence, the following conclusions are well-supported:

What We Know With Reasonable Confidence

Ashwagandha improves multiple objective and subjective sleep outcomes in controlled clinical trials. The Randhawa (2020) trial, the Badhiwala (2019) trial, and the Lopresti (2021) meta-analysis collectively represent a meaningful evidentiary foundation — not conclusive proof, but the level of evidence that appropriately drives clinical consideration in integrative medicine contexts.

The effect size is clinically meaningful but moderate. An SMD of approximately 0.59 for overall sleep quality places ashwagandha in the range of "meaningfully beneficial" for a botanical supplement. It is not the effect magnitude of a pharmaceutical hypnotic, but it is also not the trivial signal that characterizes many supplements in the research literature.

Certain populations benefit more: adults with clinical insomnia, those with stress-related sleep disruption, and potentially older adults show the most consistent and largest effects.

Effective dosing and duration are reasonably well characterized: ≥600 mg/day of standardized extract for ≥8 weeks represents the evidence-based target parameters.

The pharmacology is mechanistically credible: withanolide-mediated GABA and HPA axis effects, combined with triethylene glycol's direct sleep-promoting properties, provide a biologically plausible explanatory framework for the clinical observations.

What Remains Unknown

Long-term efficacy and safety beyond 3 months have not been adequately studied. Objective polysomnographic confirmation of the subjectively reported improvements would strengthen the evidence base considerably. Head-to-head comparisons with other sleep interventions (melatonin, cognitive behavioral therapy for insomnia, other botanicals) do not exist in the published literature.

The 2024–2026 research period — critically — has not yet produced new primary clinical trials in the indexed literature. This gap may reflect publication lags, registration of ongoing trials not yet published, or a genuine plateau in clinical research investment. The field would benefit substantially from new trials addressing the outstanding methodological limitations of the current evidence base.

Practical Guidance

For the reader considering ashwagandha as a sleep support intervention based on the available evidence:

1. Choose a standardized extract — specifically KSM-66 or another preparation with documented withanolide standardization and clinical trial evidence
2. Use a dose of 600 mg/day — either as a single dose or divided twice daily
3. Commit to a minimum of 8 weeks before evaluating whether it is working for you
4. Monitor for gastrointestinal side effects early in the treatment course; taking with food typically mitigates these
5. Consult a healthcare provider if you have liver disease, thyroid conditions, autoimmune disorders, or are pregnant
6. Do not substitute ashwagandha for evidence-based insomnia treatment — cognitive behavioral therapy for insomnia (CBT-I) remains the first-line recommendation for chronic insomnia disorder; ashwagandha may be a useful adjunct but is not a replacement

The research on ashwagandha for sleep is genuinely promising and substantively more rigorous than what exists for most botanical sleep interventions. The honest scientific assessment is that this herb produces real, measurable sleep benefits in populations likely to benefit, through mechanisms that are increasingly well-characterized, at doses and durations that are now reasonably well-defined. That is a meaningful scientific statement — and a considerably more guarded one than the breathless marketing copy surrounding this ingredient. The gap between those two characterizations is exactly why understanding the actual research matters.

This article is for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplementation program, particularly if you have pre-existing medical conditions or take prescription medications.

Related articles in the Sleep Science Series:

• Melatonin Dosing: What the Chronobiology Research Actually Shows
• L-Theanine for Sleep: Separating Mechanism from Marketing
• CBT-I: Why Behavioral Therapy Outperforms Supplements for Chronic Insomnia
• Magnesium Glycinate Sleep Research: Current Evidence Review